Table IV.
Previous studies describing the prognostic significance of the expression levels of human epidermal growth factor receptor 2 in ESCC, as determined by IHC or ISH.
| First author, year (reference) | Type of cancer | Prognostic effect | Sample size (no. of patients) | Method |
|---|---|---|---|---|
| Hardwick, 1997 (19) | ESCC, AC | No effect | 205 | IHC |
| Friess, 1999 (12) | ESCC, AC | No effect | 39 | IHC |
| Mimura, 2005 (9) | ESCC | Unfavorable | 66 | IHC, ISH |
| Reichelt, 2007 (10) | ESCC, AC | No effect | 251 | IHC, ISH |
| Sato-Kuwabara, 2009 (6) | ESCC | Unfavorable | 188 | IHC, ISH |
| Stoecklein, 2008 (37) | ESCC, AC | No effect | 101 | ISH |
| Schoppmann, 2010 (11) | ESCC, AC | No effect | 341 | IHC, ISH |
| Birner, 2011 (38) | ESCC, AC | Unfavorable | 330 | IHC, ISH |
| Zhan, 2012 (7) | ESCC | Unfavorable | 145 | IHC, ISH |
| Kato, 2013 (16) | ESCC | No effect | 245 | IHC, ISH |
| Wang, 2013 (39) | ESCC | Unfavorable | 72 | IHC |
| Wang, 1999 (18) | ESCC | No effect | 117 | IHC |
ESCC, esophageal squamous cell carcinoma; AC, adenocarcinoma; IHC, immunohistochemistry; ISH, in situ hybridization.